Whitepapers
Long-form Cybroscape thinking on AI-native validation, clinical documentation AI, Annex 22 readiness, CSA transition and the mid-market validation gap.
A whitepaper argues a position and shows the reasoning behind it. Ours cover the economics of validation for companies without a validation department, what AI-native actually means as distinct from AI-enabled, readiness for the draft EU Annex 22, how to transition from CSV to CSA, and how to evaluate clinical documentation AI.
- whitepaperThe AI-Native Validation Playbook 2026 — a Whitepaper for Life Sciences LeadersWhy the next generation of Life Sciences validation is AI-native and CSA-first — the operating model, the assurance stack, the economics, and how to phase the shift without breaking Part 11 posture.Read it
- whitepaperAI-Assisted Clinical Documentation — a Buyer's Guide for CROs and SponsorsHow to evaluate AI-assisted clinical writing platforms for CSR, protocol, safety-narrative, IB, DSUR and CER work — with the eight sponsor questions and the twelve buyer criteria that separate serious tools from demo-ware.Read it
- whitepaperEU Annex 22 Readiness — a Whitepaper on AI in GMPWhat EU Annex 22 will require of AI systems used in GMP-regulated processes — a working readiness framework, control-by-control gap assessment, and the assurance evidence regulators will look for.Read it
- whitepaperThe Mid-Market Validation Gap — an Economic WhitepaperWhy legacy validation suites cannot serve Series A–C biotech, med-device startups, CDMOs and digital-health scale-ups — and what the mid-market operating model actually looks like when engineered for velocity plus compliance.Read it
- whitepaperTransitioning to Computer Software Assurance — a Whitepaper for QA LeadersThe end-to-end CSA transition roadmap — from operating-model change and role redefinition to per-requirement risk, defensible reduction of scripted testing, and audit-ready evidence in the new world.Read it
What a whitepaper is for
A checklist tells you what to do. A whitepaper argues why, and shows the reasoning so you can disagree with it. These exist to be used in the conversation where someone has to be persuaded — a budget request, a board paper, a decision about whether to change how your organisation validates.
They are written to be read by someone who knows the subject. Where we hold a commercial position on a question, we say so in the paper rather than presenting it as neutral analysis.
How to use them
Each one is published in full on its page, so you can read it, quote it and link to it without filling in a form. Several are structured as readiness assessments you can work through against your own estate rather than as pure argument.
If you only read one and you are below enterprise scale, start with the mid-market validation economics paper — it explains why the same obligation costs you disproportionately more, and which four levers actually change the number.
Explore all resource types
Turn the reading into a plan.
Book a demo, or ask a validation lead a quick question on WhatsApp.
- We reply within one business day
- We run your URS live on the call
- You get a clear plan for your system